

**Fiscal Year 2011 (FY11) Prostate Cancer Research Program (PCRP)
Reference Table of Award Mechanisms and Submission Requirements**

PCRP AWARD MECHANISMS WITH EMPHASIS ON INNOVATION				
Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Exploration - Hypothesis Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-11-PCRP-EHDA</u></p>	<p>Investigators at or above postdoctoral fellow (or equivalent)</p>	<ul style="list-style-type: none"> • Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in prostate cancer • Emphasis is on innovation; potential impact may be unknown • Human subject studies are permitted provided the studies are exempt or eligible for expedited review • Preliminary data are strongly discouraged 	<ul style="list-style-type: none"> • Maximum funding of \$75K for direct costs (plus indirect costs) • Period of performance cannot exceed 1 year 	<p>Pre-application (Letter of Intent): May 18, 2011 5:00 p.m. Eastern Time</p> <p>Application: June 8, 2011 11:59 p.m. Eastern Time</p>
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-11-PCRP-IDA</u></p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent); <i>or</i> <i>New Investigator Option:</i> Investigators that meet the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Have the freedom to pursue individual aims without formal mentorship; <i>and</i> • Have not previously received a PCRP New Investigator Award; <i>and</i> • Have not previously received a PCRP Idea Development Award – New Investigator Option; <i>and</i> • Have either completed at least 3 years of postdoctoral training or fellowship <i>or</i> are within 5 years of having begun first independent faculty position (or equivalent) 	<ul style="list-style-type: none"> • Preproposal is required; application submission is by invitation only • Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research, and have the potential to make an important contribution to eliminating death and suffering from prostate cancer • Preliminary data are encouraged but not required • Emphasis is on Innovation and Impact • Clinical trials are not allowed • <i>New Investigator Option</i> supports applicants early in their faculty appointments or in the process of developing independent research careers 	<p>Established PIs:</p> <ul style="list-style-type: none"> • Maximum funding of \$375K for direct costs (plus indirect costs) • Period of performance cannot exceed 3 years <p>New Investigator Option:</p> <ul style="list-style-type: none"> • Maximum funding of \$225K for direct costs (plus indirect costs) • Period of performance cannot exceed 3 years 	<p>Pre-application (Preproposal): June 2, 2011 5:00 p.m. Eastern Time</p> <p>Application: August 23, 2011 11:59 p.m. Eastern Time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Synergistic Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-11-PCRP-SIDA</u></p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Preproposal is required; application submission is by invitation only • Supports new or existing partnerships between two or three independent investigators to address a central innovative question or problem in prostate cancer that may include high risk, provided there is a potential for significant impact • Preliminary data are encouraged but not required • Emphasis is on Synergy, Innovation, and Impact • Clinical trials are not allowed 	<ul style="list-style-type: none"> • Maximum funding of \$750K for direct costs (plus indirect costs) • Period of performance cannot exceed 3 years 	<p>Pre-application (Preproposal): June 2, 2011 5:00 p.m. Eastern Time</p> <p>Application: August 23, 2011 11:59 p.m. Eastern Time</p>

PCRP AWARD MECHANISMS WITH EMPHASIS ON IMPACT

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-11-PCRP-CTA</p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Preproposal is required; application submission is by invitation only • Supports rapid execution of clinical trials to test interventions (i.e., drug, device, biologic, surgical procedure, rehabilitative modality, behavioral, or other) with the potential to have a major impact on the treatment or management of prostate cancer • Studies in a broad range of areas may be submitted, including but not limited to: evaluation of novel drugs, biologics, or devices; survivorship; diet; quality of life; psychosocial interventions; and behavioral studies • Investigational New Drug or Investigational Device Exemption approvals, if applicable, must be in place before submission of the application • Sufficient study material (e.g., drug, device) must be available for the study at the time the award is made • PI must demonstrate availability and access to suitable human subject population that will support a meaningful outcome of the trial; population must be of sufficient size to clearly answer the objectives of the study • Clinical trials are expected to be initiated within 12 months of the award date 	<ul style="list-style-type: none"> • Maximum funding of \$375K for direct costs (plus indirect costs) • Period of performance cannot exceed 3 years 	<p>Pre-application (Preproposal): June 10, 2011 5:00 p.m. Eastern Time</p> <p>Application: September 1, 2011 11:59 p.m. Eastern Time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Health Disparity Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-11-PCRP-HDRA</u></p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent); <i>or</i> New Investigator Option: Investigators that meet the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Have the freedom to pursue individual aims without formal mentorship, <i>and</i> • Have not previously received a PCRP New Investigator Award, <i>and</i> • Have not received a PCRP Health Disparity Award - New Investigator Option • Have either completed at least 3 years of postdoctoral training or fellowship <i>or</i> are within 5 years of having begun first independent faculty position (or equivalent) 	<ul style="list-style-type: none"> • Supports new ideas for prostate cancer health disparity research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality • Applicants must explicitly state how the proposed research is related to an area of prostate cancer health disparity including but not limited to race and ethnicity, socioeconomic status, access to health care, insurance status, age, geography, and cultural beliefs • Preliminary data are encouraged but not required • Emphasis is on Impact and Innovation • Clinical trials are not allowed • New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers • Qualified Collaborator Option supports a higher level of funding for PIs who include a collaborator that significantly contributes to the research project such that it could not otherwise be accomplished and contributes a minimum 10% level of effort to the project 	<ul style="list-style-type: none"> • Maximum funding of \$450K for direct costs (plus indirect costs) • If applying for the Qualified Collaborator Option, maximum funding of \$600K for direct costs (plus indirect costs) • Period of performance cannot exceed 3 years 	<p>Pre-application (Letter of Intent): May 18, 2011 5:00 p.m. Eastern Time</p> <p>Application: June 8, 2011 11:59 p.m. Eastern Time</p>
<p>Impact Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-11-PCRP-IA</u></p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Preproposal is required; application submission is by invitation only • Supports high-impact studies (including clinical trials) toward reducing or eliminating the problem of overtreatment of primary prostate cancer • Areas of interest include but are not limited to development/improvement of surveillance mechanisms, biomarkers, improved staging (including imaging), optimal measures to inform decision-making pre- and post-biopsy, optimal measures for follow-up and assessment of progression, and cancer care outcomes research (e.g., quality of life, survivorship) and surveillance • Multidisciplinary teams inclusive of clinical specialists are a key feature • Preliminary data to support feasibility are required 	<ul style="list-style-type: none"> • Maximum funding of \$750K for direct costs (plus indirect costs) • Period of performance cannot exceed 5 years 	<p>Pre-application (Preproposal): June 10, 2011 5:00 p.m. Eastern Time</p> <p>Application: September 1, 2011 11:59 p.m. Eastern Time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Laboratory - Clinical Transition Award (<i>Modified!</i>)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-11-PCR-P-LCTA</p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Preproposal is required; application submission is by invitation only • Supports product-driven preclinical studies of promising lead agents that have the potential to revolutionize prostate cancer clinical care • PIs are expected to demonstrate within the application (1) a validated target, (2) access to either one lead agent or a limited number of lead agents for optimization, and (3) the agent's mechanism of action • Preliminary data are required to demonstrate validated target availability and distribution in relevant human tissues and substantive information from model systems that supports potential efficacy of the lead agent(s) in humans • Does not support target discovery, drug screening, device development, development of diagnostic biomarkers, studies of new combinations of conventional therapeutics in clinical testing or practice, or clinical trials <p>(New for FY11!) Supports research that ranges from preclinical study of the lead agent(s) through its cGMP production</p>	<ul style="list-style-type: none"> • Maximum funding of \$750K for direct costs (plus indirect costs) • Period of performance cannot exceed 3 years 	<p>Pre-application (Preproposal): June 10, 2011 5:00 p.m. Eastern Time</p> <p>Application: September 1, 2011 11:59 p.m. Eastern Time</p>

<p>Population-Based Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p><u>W81XWH-11-PCRP-PBRA</u></p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports high-impact approaches to prostate cancer research from the perspective of population-based studies that will, if successful, significantly accelerate the elimination of death and suffering from prostate cancer • Population-based studies may include retrospective, prospective, case-control, cohort, or other population-based study designs (including the use of biospecimens and data from established retrospective databases), provided that the sample of a defined patient population is of sufficient size to demonstrate statistical significance • Topics may include but are not limited to biomarkers, predictors of response to therapy, disease aggressiveness, epidemiology, germline or somatic genomics, health disparity, molecular genetics, risk prediction • Requires a robust statistical plan and strong biostatistical expertise in the study team • Emphasis is on Impact and Research Strategy and Feasibility • Clinical trials are not allowed 	<ul style="list-style-type: none"> • Maximum funding of \$600K for direct costs (plus indirect costs) • Period of performance cannot exceed 4 years 	<p>Pre-application (Letter of Intent): May 18, 2011 5:00 p.m. Eastern Time</p> <p>Application: June 8, 2011 11:59 p.m. Eastern Time</p>
---	---	--	---	---

PCRP AWARD MECHANISMS WITH EMPHASIS ON TRAINING

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Collaborative Undergraduate Historically Black Colleges and Universities (HBCU) Student Summer Training Program Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-11-PCRP-STPA</u></p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent) with a proven record in prostate cancer research and training</p>	<ul style="list-style-type: none"> • Supports new or existing summer training programs for undergraduate HBCU students at host institutions with thriving prostate cancer research programs • Must enroll a minimum of four undergraduate HBCU trainees per year • Host institution must have a record of achievement in prostate cancer research and training 	<ul style="list-style-type: none"> • Maximum funding of \$185K for direct costs (plus indirect costs up to a maximum rate of 8%) • Period of performance cannot exceed 3 years 	<p>Pre-application (Letter of Intent): May 18, 2011 5:00 p.m. Eastern Time</p> <p>Application: June 8, 2011 11:59 p.m. Eastern Time</p>
<p>Health Disparity Training Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-11-PCRP-HDTA</u></p>	<p>Predoctoral Ph.D. and M.D./Ph.D. PIs:</p> <ul style="list-style-type: none"> • Must be enrolled full-time in an accredited doctoral program and must have completed all predissertation requirements by October 1, 2011 <p>Postdoctoral Ph.D., M.D., and M.D./Ph.D. PIs:</p> <ul style="list-style-type: none"> • Must have successfully defended a doctoral thesis or possess an M.D. degree by October 1, 2011; <i>and</i> • Have <i>3 years or less</i> of postdoctoral fellowship experience by October 1, 2011 	<ul style="list-style-type: none"> • Supports predoctoral and postdoctoral training in prostate cancer health disparity research for individuals in the early stages of their careers • PIs must have a <i>designated mentor</i> who is an experienced prostate cancer health disparity researcher • Applicants must explicitly state how the proposed research is related to an area of prostate cancer health disparity including but not limited to race and ethnicity, socioeconomic status, access to health care, insurance status, age, geography, and cultural beliefs • Emphasis is on PI, Mentor, Training Program and Environment, and Research Strategy and Feasibility 	<p>Predoctoral Ph.D. and M.D./Ph.D. PIs:</p> <ul style="list-style-type: none"> • Maximum funding of \$92.5K for direct costs (plus indirect costs up to a maximum rate of 8%) • Period of performance cannot exceed 3 years <p>Postdoctoral Ph.D., M.D., and M.D./Ph.D. PIs:</p> <ul style="list-style-type: none"> • Maximum of \$115K for direct costs (plus indirect costs up to a maximum rate of 8%) • Period of performance cannot exceed 2 years 	<p>Pre-application (Letter of Intent): May 18, 2011 5:00 p.m. Eastern Time</p> <p>Confidential Letters of Recommendation: June 8, 2011 5:00 p.m. Eastern Time</p> <p>Application: June 8, 2011 11:59 p.m. Eastern Time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Physician Research Training Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-11-PCRP-PRTA</u></p>	<p>At the time of application submission, the PI must be either:</p> <ul style="list-style-type: none"> • In the last year of an accredited medical residency or medical fellowship program; or • Within 3 years of having initiated an appointment as Instructor, Assistant Professor, or equivalent 	<ul style="list-style-type: none"> • Supports training of physicians with clinical duties for careers in prostate cancer research • PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice • PIs must have a <i>designated mentor</i> with an established research program in prostate cancer • Institutions must provide at least 40% protection of PI's time for research • Emphasis is on PI, Mentor, Training Program and Environment, and Research Strategy and Feasibility 	<ul style="list-style-type: none"> • Maximum funding of \$130K per year for direct costs (plus indirect costs up to a maximum rate of 8%) • Period of performance is 3 years minimum to 5 years maximum 	<p>Pre-application (Letter of Intent): May 18, 2011 5:00 p.m. Eastern Time</p> <p>Confidential Letters of Recommendation: June 8, 2011 5:00 p.m. Eastern Time</p> <p>Application: June 8, 2011 11:59 p.m. Eastern Time</p>
<p>Postdoctoral Training Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-11-PCRP-PTA</u></p>	<p><i>By October 1, 2011</i>, the PI must:</p> <ul style="list-style-type: none"> • Have successfully defended a doctoral thesis or posses an M.D. degree; <i>and</i> • Have 3 years or less of postdoctoral fellowship experience 	<ul style="list-style-type: none"> • Supports postdoctoral training in prostate cancer research for recent doctoral graduates • PIs must have a <i>designated mentor</i> who is an experienced prostate cancer researcher • Emphasis is on PI, Mentor, Training Program and Environment, and Research Strategy and Feasibility 	<p>Postdoctoral M.D. or Ph.D. PIs:</p> <ul style="list-style-type: none"> • Maximum of \$115K for direct costs (plus indirect costs up to a maximum rate of 8%) • Period of performance cannot exceed 2 years 	<p>Pre-application (Letter of Intent): May 18, 2011 5:00 p.m. Eastern Time</p> <p>Confidential Letters of Recommendation: June 8, 2011 5:00 p.m. Eastern Time</p> <p>Application: June 8, 2011 11:59 p.m. Eastern Time</p>